{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:03:25Z","timestamp":1791475405784,"version":"4.3.4"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T00:00:00Z","timestamp":1515369600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00223-017-0335-7","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T14:06:03Z","timestamp":1515420363000},"page":"592-606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Glucocorticoids, Inflammation and Bone"],"prefix":"10.1007","volume":"102","author":[{"given":"Melek","family":"G\u00fcler-Y\u00fcksel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos N.","family":"Hoes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene E.M.","family":"Bultink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem F.","family":"Lems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,8]]},"reference":[{"key":"335_CR1","first-page":"1982","volume":"50","author":"L Fardet","year":"2011","unstructured":"Fardet L, Petersen I, Nazareth I (2011) Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20\u00a0years. Oxford, England 50:1982\u20131990","journal-title":"Oxford, England"},{"key":"335_CR2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11914-012-0104-5","volume":"10","author":"T Braun","year":"2012","unstructured":"Braun T, Schett G (2012) Pathways for bone loss in inflammatory disease. Current osteoporosis reports 10:101\u2013108","journal-title":"Current osteoporosis reports"},{"key":"335_CR3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200084","volume":"13","author":"TP Staa Van","year":"2002","unstructured":"Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis Int 13:777\u20137787","journal-title":"Osteoporosis Int"},{"key":"335_CR4","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","volume":"48","author":"TP Staa Van","year":"2003","unstructured":"Van Staa TP, Laan RF, Barton IP et al (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224\u20133229","journal-title":"Arthritis Rheum"},{"key":"335_CR5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/ijr.14.24","volume":"9","author":"NO Kuchuk","year":"2014","unstructured":"Kuchuk NO, Hoes JN, Bijlsma JW, Jacobs JW (2014) Glucocorticoid-induced osteoporosis: an overview. Int J Clin Rheum 9:311\u2013326","journal-title":"Int J Clin Rheum"},{"key":"335_CR6","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/en.2003-0990","volume":"145","author":"CA O\u2019Brien","year":"2004","unstructured":"O\u2019Brien CA, Jia D, Plotkin LI et al (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835\u20131841","journal-title":"Endocrinology"},{"key":"335_CR7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bbrc.2005.01.117","volume":"329","author":"K Ohnaka","year":"2005","unstructured":"Ohnaka K, Tanabe M, Kawate H et al (2005) Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329:177\u2013181","journal-title":"Biochem Biophys Res Commun"},{"key":"335_CR8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1471-2474-11-210","volume":"11","author":"JS Butler","year":"2010","unstructured":"Butler JS, Queally JM, Devitt BM et al (2010) Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation. BMC musculoskeletal disorders 11:210","journal-title":"BMC musculoskeletal disorders"},{"key":"335_CR9","doi-asserted-by":"crossref","unstructured":"Komori T (2016) Glucocorticoid Signaling and Bone Biology. Hormone and metabolic research\u00a0=\u00a0Hormon- und Stoffwechselforschung\u00a0=\u00a0Hormones et metabolisme 48: 755-763","DOI":"10.1055\/s-0042-110571"},{"issue":"3","key":"335_CR10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/JME-14-0314","volume":"54","author":"C Shi","year":"2015","unstructured":"Shi C, Huang P, Kang H et al (2015) Glucocorticoid inhibits cell proliferation in differentiating osteoblasts by microRNA-199a targeting of WNT signaling. J Mol Endocrinol 54(3):325\u2013337","journal-title":"J Mol Endocrinol"},{"key":"335_CR11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S8756-3282(02)00687-7","volume":"30","author":"RC Pereira","year":"2002","unstructured":"Pereira RC, Delany AM, Canalis E (2002) Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 30:685\u2013691","journal-title":"Bone"},{"key":"335_CR12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/(SICI)1097-4644(20000301)76:3<518::AID-JCB18>3.0.CO;2-M","volume":"76","author":"XM Shi","year":"2000","unstructured":"Shi XM, Blair HC, Yang X et al (2000) Tandem repeat of C\/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-induced adipocyte differentiation. J Cell Biochem 76:518\u2013527","journal-title":"J Cell Biochem"},{"key":"335_CR13","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/jbmr.120","volume":"25","author":"I Carcamo-Orive","year":"2010","unstructured":"Carcamo-Orive I, Gaztelumendi A, Delgado J et al (2010) Regulation of human bone marrow stromal cell proliferation and differentiation capacity by glucocorticoid receptor and AP-1 crosstalk. J bone miner res 25:2115\u20132125","journal-title":"J bone miner res"},{"key":"335_CR14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1517\/14656566.2013.761975","volume":"14","author":"IE Bultink","year":"2013","unstructured":"Bultink IE, Baden M, Lems WF (2013) Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother 14:185\u2013197","journal-title":"Expert Opin Pharmacother"},{"key":"335_CR15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrendo.2012.89","volume":"8","author":"SL Teitelbaum","year":"2012","unstructured":"Teitelbaum SL (2012) Bone: the conundrum of glucocorticoid-induced osteoporosis. Nat reviews Endocrinol 8:451\u2013452","journal-title":"Nat reviews Endocrinol"},{"key":"335_CR16","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","volume":"140","author":"LC Hofbauer","year":"1999","unstructured":"Hofbauer LC, Gori F, Riggs BL et al (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382\u20134389","journal-title":"Endocrinology"},{"key":"335_CR17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/jcb.21414","volume":"103","author":"T Kondo","year":"2008","unstructured":"Kondo T, Kitazawa R, Yamaguchi A et al (2008) Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J Cell Biochem 103:335\u2013345","journal-title":"J Cell Biochem"},{"key":"335_CR18","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI28084","volume":"116","author":"HJ Kim","year":"2006","unstructured":"Kim HJ, Zhao H, Kitaura H et al (2006) Glucocorticoids suppress bone formation via the osteoclast. J Clin Investig 116:2152\u20132160","journal-title":"J Clin Investig"},{"key":"335_CR19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/art.30135","volume":"63","author":"SL Teitelbaum","year":"2011","unstructured":"Teitelbaum SL, Seton MP, Saag KG (2011) Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum 63:325\u2013328","journal-title":"Arthritis Rheum"},{"key":"335_CR20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00223-012-9684-4","volume":"92","author":"K Brabnikova Maresova","year":"2013","unstructured":"Brabnikova Maresova K, Pavelka K et al (2013) Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes. Calcif Tissue Int 92:354\u2013361","journal-title":"Calcif Tissue Int"},{"key":"335_CR21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1530\/eje.1.01841","volume":"152","author":"S Bonadonna","year":"2005","unstructured":"Bonadonna S, Burattin A, Nuzzo M et al (2005) Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol 152:199\u2013205","journal-title":"Eur J Endocrinol"},{"key":"335_CR22","first-page":"109","volume":"35","author":"S Whirledge","year":"2010","unstructured":"Whirledge S, Cidlowski JA (2010) Glucocorticoids, stress, and fertility. Minerva Endocrinol 35:109\u2013125","journal-title":"Minerva Endocrinol"},{"key":"335_CR23","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.biocel.2013.05.036","volume":"45","author":"O Schakman","year":"2013","unstructured":"Schakman O, Kalista S, Barbe C et al (2013) Glucocorticoid-induced skeletal muscle atrophy. The international journal of biochemistry & cell biology 45:2163\u20132172","journal-title":"The international journal of biochemistry & cell biology"},{"key":"335_CR24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/JBMR.041230","volume":"20","author":"P Szulc","year":"2005","unstructured":"Szulc P, Beck TJ, Marchand F et al (2005) Low skeletal muscle mass is associated with poor structural parameters of bone and impaired balance in elderly men\u2013the MINOS study. J bone miner res 20:721\u2013729","journal-title":"J bone miner res"},{"key":"335_CR25","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1002\/art.20583","volume":"50","author":"F Buttgereit","year":"2004","unstructured":"Buttgereit F, Straub RH, Wehling M et al (2004) Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 50:3408\u20133417","journal-title":"Arthritis Rheum"},{"key":"335_CR26","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Then","year":"2005","unstructured":"Then T, Ja Cidlowski (2005) Antiinflammatory action of glucocorticoids\u2013new mechanisms for old drugs. N Engl J Med 353:1711\u20131723","journal-title":"N Engl J Med"},{"key":"335_CR27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ncprheum0898","volume":"4","author":"C Stahn","year":"2008","unstructured":"Stahn C, Buttgereit F (2008) Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 4:525\u2013533","journal-title":"Nat Clin Pract Rheumatol"},{"key":"335_CR28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","volume":"335","author":"AE Coutinho","year":"2011","unstructured":"Coutinho AE, Chapman KE (2011) The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 335:2\u201313","journal-title":"Mol Cell Endocrinol"},{"key":"335_CR29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","volume":"17","author":"DW Cain","year":"2017","unstructured":"Cain DW, Cidlowski JA (2017) Immune regulation by glucocorticoids. Nat Rev Immunol 17:233\u2013247","journal-title":"Nat Rev Immunol"},{"key":"335_CR30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1042\/cs0940557","volume":"94","author":"PJ Barnes","year":"1998","unstructured":"Barnes PJ (1998) Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 94:557\u2013572","journal-title":"Clin Sci (Lond)"},{"key":"335_CR31","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977","journal-title":"Ann Rheum Dis"},{"key":"335_CR32","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1\u201326","journal-title":"Arthritis Rheumatol"},{"key":"335_CR33","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard.2006.069252","volume":"66","author":"T Sokka","year":"2007","unstructured":"Sokka T, Kautiainen H, Toloza S et al (2007) QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 66:1491\u20131496","journal-title":"Ann Rheum Dis"},{"key":"335_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001158","author":"LA Criswell","year":"2004","unstructured":"Criswell LA, Saag KG, Sems KM et al (2004) Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001158","journal-title":"Cochrane Database Syst Rev"},{"key":"335_CR35","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1136\/annrheumdis-2016-210647","volume":"76","author":"M Safy","year":"2017","unstructured":"Safy M, Jacobs J, Ijff ND et al (2017) Long-term outcome is better when a methotrexate-based treatment is combined with 10\u00a0mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial. Ann Rheum Dis 76:1432\u20131435","journal-title":"Ann Rheum Dis"},{"key":"335_CR36","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YPM Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381\u20133390","journal-title":"Arthritis Rheum"},{"key":"335_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","volume":"136","author":"AA Everdingen Van","year":"2002","unstructured":"Van Everdingen AA, Jacobs JWG, Siewertsz van Reesema DR et al (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136:1\u201312","journal-title":"Ann Intern Med"},{"key":"335_CR38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","volume":"350","author":"M Boers","year":"1997","unstructured":"Boers M, Verhoeven AC, Markusse HM et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309\u2013318","journal-title":"Lancet"},{"key":"335_CR39","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/rheumatology\/keu135","volume":"53","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Wells AF (2014) Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis. Rheumatol 53:1742\u20131751","journal-title":"Rheumatol"},{"key":"335_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006356","author":"JR Kirwan","year":"2007","unstructured":"Kirwan JR, Bijlsma JW, Boers M et al (2007) Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD006356","journal-title":"Cochrane Database Syst Rev"},{"key":"335_CR41","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/art.21809","volume":"54","author":"JW Jacobs","year":"2006","unstructured":"Jacobs JW, van Everdingen AA, Verstappen SM et al (2006) Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 54:1422\u20131428","journal-title":"Arthritis Rheum"},{"key":"335_CR42","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2008.087833","volume":"68","author":"I Hafstrom","year":"2009","unstructured":"Hafstrom I, Albertsson K, Bonnen A et al (2009) Remission achieved after 2\u00a0years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4\u00a0years: an open 2-year continuation study. Ann Rheum Dis 68:508\u2013513","journal-title":"Ann Rheum Dis"},{"key":"335_CR43","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/ard.2009.108027","volume":"69","author":"LH Tuyl Van","year":"2010","unstructured":"Van Tuyl LH, Boers M, Lems WF et al (2010) Survival, comorbidities and joint damage 11\u00a0years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 69:807\u2013812","journal-title":"Ann Rheum Dis"},{"issue":"suppl 1","key":"335_CR44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s003930070036","volume":"59","author":"R Westhovens","year":"2000","unstructured":"Westhovens R, Dequeker J (2000) Rheumatoid arthritis and osteoporosis. Z Rheumatol 59(suppl 1):33\u201338","journal-title":"Z Rheumatol"},{"key":"335_CR45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/berh.2000.0129","volume":"15","author":"MJ Green","year":"2001","unstructured":"Green MJ, Deodhar AA (2001) Bone changes in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 15:105\u2013123","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"335_CR46","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y","volume":"43","author":"G Haugeberg","year":"2000","unstructured":"Haugeberg G, Uhlig T, Falch JA et al (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 43:522\u2013530","journal-title":"Arthritis Rheum"},{"key":"335_CR47","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1002\/1529-0131(200012)43:12<2776::AID-ANR18>3.0.CO;2-N","volume":"43","author":"G Haugeberg","year":"2000","unstructured":"Haugeberg G, Uhlig T, Falch JA et al (2000) Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 43:2776\u20132784","journal-title":"Arthritis Rheum"},{"key":"335_CR48","first-page":"2590","volume":"30","author":"K Forslind","year":"2003","unstructured":"Forslind K, Keller C, Svensson B et al (2003) Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2\u00a0years in women. J Rheumatol 30:2590\u20132596","journal-title":"J Rheumatol"},{"key":"335_CR49","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/03009740801998747","volume":"37","author":"C Book","year":"2008","unstructured":"Book C, Karlsson M, Akesson K et al (2008) Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis. Scand J Rheumatol 37:248\u2013254","journal-title":"Scand J Rheumatol"},{"key":"335_CR50","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00198-012-2073-z","volume":"24","author":"MC Goes Van der","year":"2013","unstructured":"Van der Goes MC, Jacobs JW, Jurgens MS et al (2013) Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporosis Int 24:1429\u20131436","journal-title":"Osteoporosis Int"},{"key":"335_CR51","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2007.073817","volume":"67","author":"M Guler-Yuksel","year":"2008","unstructured":"Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP et al (2008) Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 67:823\u2013828","journal-title":"Ann Rheum Dis"},{"key":"335_CR52","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/art.23951","volume":"58","author":"G Schett","year":"2008","unstructured":"Schett G, Stach C, Zwerina J et al (2008) How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Artthritis Rheum 58:2936\u20132948","journal-title":"Artthritis Rheum"},{"key":"335_CR53","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/ard.2010.135061","volume":"69","author":"G Schett","year":"2010","unstructured":"Schett G, Kaag KG, Bijlsma JW (2010) From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis 69:1415\u20131419","journal-title":"Ann Rheum Dis"},{"key":"335_CR54","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00198-013-2334-5","volume":"24","author":"M Vis","year":"2013","unstructured":"Vis M, Guler-Yuksel M, Lems WF (2013) Can bone loss in rheumatoid arthritis be prevented? Osteoporosis Int 24:2541\u20132553","journal-title":"Osteoporosis Int"},{"key":"335_CR55","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","volume":"54","author":"TP Staa Van","year":"2006","unstructured":"Van Staa TP, Geusens P, Bijlsma JW et al (2006) Clinical assessment of the longterm risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104\u20133112","journal-title":"Arthritis Rheum"},{"key":"335_CR56","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200084","volume":"13","author":"TP Staa Van","year":"2002","unstructured":"Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777\u2013787","journal-title":"Osteoporos Int"},{"key":"335_CR57","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/ard.48.7.535","volume":"48","author":"PN Sambrook","year":"1989","unstructured":"Sambrook PN, Cohen ML, Eisman JA et al (1989) Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis 48:535\u2013538","journal-title":"Ann Rheum Dis"},{"key":"335_CR58","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/rheumatology\/40.11.1231","volume":"40","author":"AC Verhoeven","year":"2001","unstructured":"Verhoeven AC, Boers M, te Koppele JM et al (2001) Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisone. Rheumatol 40:1231\u20131237","journal-title":"Rheumatol"},{"key":"335_CR59","first-page":"1495","volume":"24","author":"AC Verhoeven","year":"1997","unstructured":"Verhoeven AC, Boers M (1997) Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol 24:1495\u20131503","journal-title":"J Rheumatol"},{"key":"335_CR60","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-004-0989-1","volume":"24","author":"GS Habib","year":"2005","unstructured":"Habib GS, Haj S (2005) Bone mineral density in patients with early arthritis treated with corticosteroids. Clin Rheumatol 24:129\u2013133","journal-title":"Clin Rheumatol"},{"key":"335_CR61","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archinte.165.11.1293","volume":"165","author":"G Haugeberg","year":"2005","unstructured":"Haugeberg G, Strand A, Kvien TK et al (2005) Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch Intern Med 165:1293\u20131297","journal-title":"Arch Intern Med"},{"key":"335_CR62","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/ard.2007.086348","volume":"68","author":"M Guler-Yuksel","year":"2009","unstructured":"Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP et al (2009) Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68:330\u2013336","journal-title":"Ann Rheum Dis"},{"key":"335_CR63","unstructured":"Linda Hartman, Linda A. Rasch, Thomas Klausch, et al (submitted) Harm and benefit associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): Design of a 2-year multicentre, double-blind, randomised controlled trial"},{"key":"335_CR64","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.61.1.32","volume":"61","author":"B Gudbjornsson","year":"2002","unstructured":"Gudbjornsson B, Juliusson UI, Gudjonsson FV (2002) Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 61:32\u201336","journal-title":"Ann Rheum Dis"},{"key":"335_CR65","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMcp1012926","volume":"365","author":"RS Weinstein","year":"2011","unstructured":"Weinstein RS (2011) Clinical practice. glucocorticoid-induced bone disease. N Engl J Med 365:62\u201370","journal-title":"N Engl J Med"},{"key":"335_CR66","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"Canalis E, Mazziotti G, Giustina A et al (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319\u20131328","journal-title":"Osteoporos Int"},{"key":"335_CR67","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/archinte.166.22.2495","volume":"166","author":"G Schett","year":"2006","unstructured":"Schett G, Kiechl S, Weger S et al (2006) High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 166:2495\u20132501","journal-title":"Arch Intern Med"},{"key":"335_CR68","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jbmr.2037","volume":"29","author":"AL Eriksson","year":"2014","unstructured":"Eriksson AL, Moverare-Skrtic S, Ljunggren \u00d6 et al (2014) High-sensitivity CRP is an independent risk factor for all fractures and vertebral fractures in elderly men: the MrOS Sweden study. J Bone Miner Res 29:418\u2013423","journal-title":"J Bone Miner Res"},{"key":"335_CR69","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/03009742.2013.852239","volume":"43","author":"NPC Konijn","year":"2014","unstructured":"Konijn NPC, van Tuyl LHD, Bultink IEM et al (2014) Making the invisible visible: bioelectrical impedance analysis demonstrates unfavourable body composition in rheumatoid arthritis patients in clinical practice. Scand J Rheumatol 43:273\u2013278","journal-title":"Scand J Rheumatol"},{"key":"335_CR70","doi-asserted-by":"crossref","first-page":"e000186","DOI":"10.1136\/lupus-2016-000186","volume":"4","author":"PP Katz","year":"2017","unstructured":"Katz PP, Andrews J, Yazdany J et al (2017) Is frailty a relevant concept in SLE? Lupus Sci Med 4:e000186","journal-title":"Lupus Sci Med"},{"key":"335_CR71","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Staa Van","year":"2000","unstructured":"Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993\u20131000","journal-title":"J Bone Miner Res"},{"key":"335_CR72","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-003-1548-3","volume":"15","author":"M Steinbuch","year":"2004","unstructured":"Steinbuch M, Youket TE, Cohen S (2004) Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 15:323\u2013328","journal-title":"Osteoporos Int"},{"key":"335_CR73","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/art.22294","volume":"56","author":"F Vries de","year":"2007","unstructured":"de Vries F, Bracke M, Leufkens HG et al (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208\u2013214","journal-title":"Arthritis Rheum"},{"key":"335_CR74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/qjmed\/93.2.105","volume":"93","author":"TP Staa Van","year":"2000","unstructured":"Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids in the United Kingdom. QJM 93:105\u2013111","journal-title":"QJM"},{"key":"335_CR75","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/qjmed\/hci029","volume":"98","author":"TP Staa Van","year":"2005","unstructured":"Van Staa TP, Geusens P, Pols HA et al (2005) A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 98:191\u2013198","journal-title":"QJM"},{"key":"335_CR76","unstructured":"https:\/\/www.shef.ac.uk\/FRAX\/tool.jsp"},{"key":"335_CR77","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden H et al (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporosis Int 22:809\u2013816","journal-title":"Osteoporosis Int"},{"key":"335_CR78","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/archinte.164.4.420","volume":"164","author":"RE Orstavik","year":"2004","unstructured":"Orstavik RE, Haugeberg G, Mowinckel P et al (2004) Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls. Arch Intern Med 164:420\u2013425","journal-title":"Arch Intern Med"},{"key":"335_CR79","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","volume":"62","author":"JM Grossmann","year":"2010","unstructured":"Grossmann JM, Gordon R, Ranganath VK et al (2010) American college of rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:1515\u20131526","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"335_CR80","volume-title":"Clinician\u2019s guide to the prevention and treatment of osteoporosis","author":"F Cosman","year":"2009","unstructured":"Cosman F, de Beur SJ, LeBoff MS (2009) Clinician\u2019s guide to the prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington DC"},{"key":"335_CR81","volume-title":"Guidelines on the prevention and treatment of glucocorticoid-induced osteoporosis","author":"Bone and tooh society of Great Britain","year":"2003","unstructured":"Bone and tooh society of Great Britain (2003) Guidelines on the prevention and treatment of glucocorticoid-induced osteoporosis. Royal College of Physicians, London"},{"key":"335_CR82","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00198-005-2032-z","volume":"17","author":"JP Devogelaer","year":"2006","unstructured":"Devogelaer JP, Goemaere S, Boonen S et al (2006) Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17:8\u201319","journal-title":"Osteoporos Int"},{"key":"335_CR83","unstructured":"Dutch CBO guideline osteoporosis and fracture prevention. 2011. www.cbo.nl\/en\/Guidelines"},{"key":"335_CR84","unstructured":"Finnish national guidelines for treatment of osteoporosis. 2006. www.kaypahoim.fi\/web\/english\/guidelines"},{"key":"335_CR85","unstructured":"DVO Guideline 2009 for prevention, diagnosis and therapy of osteoporosis in adults. www.dv-osteologie.org\/dvo_leitlinien\/dvo-leitlinie-2009"},{"key":"335_CR86","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","volume":"23","author":"Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Joint IOF-ECTS GIO Guidelines Working Group","year":"2012","unstructured":"Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Joint IOF-ECTS GIO Guidelines Working Group (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257\u20132276","journal-title":"Osteoporos Int"},{"issue":"8","key":"335_CR87","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/acr.23279","volume":"69","author":"L Buckley","year":"2017","unstructured":"Buckley L, Gyuatt G, Fink HA et al (2017) 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 69(8):1521\u20131537","journal-title":"Arthritis Care Res"},{"key":"335_CR88","first-page":"1500","volume":"66","author":"JN Hoes","year":"2007","unstructured":"Hoes JN, Jacobs JW, Boers M et al (2007) EULAR-evidence based recommendations on the management of systemic glucocorticoid-therapy in rheumatic diseases. Ann Rheum Dis 66:1500\u20131507","journal-title":"Ann Rheum Dis"},{"key":"335_CR89","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","volume":"141","author":"R Caporali","year":"2004","unstructured":"Caporali R, Cimmino MA, Ferraccioli G et al (2004) Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Int Med 141:493\u2013500","journal-title":"Ann Int Med"},{"key":"335_CR90","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","volume":"23","author":"S Lekenwasam","year":"2012","unstructured":"Lekenwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of GIOP. Osteoporosis Int 23:2257\u20132276","journal-title":"Osteoporosis Int"},{"key":"335_CR91","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-011-1545-x","volume":"22","author":"JJ Body","year":"2011","unstructured":"Body JJ, Bergmann P, Boonen S et al (2011) Non-pharmacological management of osteoporosis: a consensus of the belgian bone club. Osteoporos Int 22:2769\u20132788","journal-title":"Osteoporos Int"},{"key":"335_CR92","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/ard.2007.072157","volume":"66","author":"JN Hoes","year":"2007","unstructured":"Hoes JN, Jacobs JW, Boers M et al (2007) EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66:1560\u20131567","journal-title":"Ann Rheum Dis"},{"key":"335_CR93","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11926-011-0173-y","volume":"13","author":"D Uyl Den","year":"2011","unstructured":"Den Uyl D, Bultink IEM, Lems WF (2011) Advances in glucocorticoid induced osteoporosis. Curr Rheumatol Rep 13:233\u2013240","journal-title":"Curr Rheumatol Rep"},{"key":"335_CR94","first-page":"e00014","volume":"1","author":"K Briot","year":"2015","unstructured":"Briot K, Roux C (2015) Glucocorticoid induced osteoporosis. RMD open 1:e00014","journal-title":"Glucocorticoid induced osteoporosis. RMD open"},{"key":"335_CR95","doi-asserted-by":"crossref","first-page":"961","DOI":"10.7326\/0003-4819-125-12-199612150-00004","volume":"125","author":"LM Buckley","year":"1996","unstructured":"Buckley LM, Leib ES, Cartularo KS et al (1996) Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low dose GC in RA. Ann Int Med 125:961\u2013968","journal-title":"Ann Int Med"},{"key":"335_CR96","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-016-0221-8","volume":"100","author":"LA Rasch","year":"2017","unstructured":"Rasch LA, de van der Schueren MA, van Tuyl LH et al (2017) Content validity of a short calcium intake list to estimate daily dietary calcium intake of patients with osteoporosis. Calcif Tissue Int 100:271\u2013277","journal-title":"Calcif Tissue Int"},{"key":"335_CR97","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/joim.12394","volume":"278","author":"IR Reid","year":"2015","unstructured":"Reid IR, Bristow SM, Bolland MJ (2015) Calcium supplements: benefits and risks. J Intern Med 278:354\u2013368","journal-title":"J Intern Med"},{"key":"335_CR98","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10067-009-1328-3","volume":"29","author":"D Uyl den","year":"2010","unstructured":"den Uyl D, Geusens PP, van Berkum FN et al (2010) Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial. Clin Rheumatol 29:465\u2013472","journal-title":"Clin Rheumatol"},{"key":"335_CR99","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.beem.2011.06.007","volume":"25","author":"NM Schoor Van","year":"2011","unstructured":"Van Schoor NM, Lips P (2011) Worldwide vitamin D status. Best Pract Res Clin Endocrinol Metab 25:671\u2013680","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"335_CR100","doi-asserted-by":"crossref","first-page":"e0146351","DOI":"10.1371\/journal.pone.0146351","volume":"11","author":"J Lin","year":"2016","unstructured":"Lin J, Liu J, Davies ML et al (2016) Serum vitamin D level and rheumatoid arthritis disease activity: review and meta-analysis. PLoS ONE 11:e0146351","journal-title":"PLoS ONE"},{"key":"335_CR101","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa1109617","volume":"367","author":"HA Bischoff-Ferrari","year":"2012","unstructured":"Bischoff-Ferrari HA, Willett WC, Orav EJ et al (2012) A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 367:40\u201349","journal-title":"N Engl J Med"},{"key":"335_CR102","doi-asserted-by":"crossref","first-page":"b3692","DOI":"10.1136\/bmj.b3692","volume":"339","author":"HA Bischoff-Ferrari","year":"2009","unstructured":"Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB et al (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 339:b3692","journal-title":"BMJ"},{"key":"335_CR103","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jama.2010.594","volume":"303","author":"KM Sanders","year":"2010","unstructured":"Sanders KM, Stuart AL, Williamson EJ et al (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303:1815\u20131822","journal-title":"JAMA"},{"key":"335_CR104","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jamainternmed.2015.7148","volume":"176","author":"HA Bischoff-Ferrari","year":"2016","unstructured":"Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ et al (2016) Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline: a Randomized Clinical Trial. JAMA Intern Med 176:175\u2013183","journal-title":"JAMA Intern Med"},{"key":"335_CR105","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1056\/NEJM199306173282404","volume":"328","author":"P Sambrook","year":"1993","unstructured":"Sambrook P, Birmingham J, Kelly P et al (1993) Prevention of Glucocorticoid Osteoporosis: a comparison of calcium, calcitriol and calcitonin. New Engl J Med 328:1747\u20131752","journal-title":"New Engl J Med"},{"key":"335_CR106","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMoa053569","volume":"355","author":"RN Nijs de","year":"2006","unstructured":"de Nijs RN, Jacobs JW, Lems WF et al (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355:675\u2013684","journal-title":"N Engl J Med"},{"key":"335_CR107","first-page":"14","volume":"109","author":"M Brotto","year":"2015","unstructured":"Brotto M, Bonewald L (2015) Bone and muscle: interactions beyond mechanical. Bone 109:14","journal-title":"Bone"},{"key":"335_CR108","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12020-013-0026-8","volume":"45","author":"L Cianferotti","year":"2014","unstructured":"Cianferotti L, Brandi ML (2014) Muscle bone interactions: basic and clinical aspects. Endocrine 45:165\u2013177","journal-title":"Endocrine"},{"key":"335_CR109","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s00198-012-1940-y","volume":"23","author":"V Yoon","year":"2012","unstructured":"Yoon V, Maalouf NM, Sakhaee K (2012) The effects of smoking on bone metabolism. Osteoporos Int 23:2081\u20132092","journal-title":"Osteoporos Int"},{"key":"335_CR110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johnell O, Oden A et al (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155\u2013162","journal-title":"Osteoporos Int"},{"key":"335_CR111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-011-1787-7","volume":"23","author":"DB Maurel","year":"2012","unstructured":"Maurel DB, Boisseau N, Benhamou CL et al (2012) Alcohol and bone: review of dose effects and mechanisms. Osteoporos Int 23:1\u201316","journal-title":"Osteoporos Int"},{"key":"335_CR112","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00198-004-1734-y","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johansson H, Johnell O et al (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737\u2013742","journal-title":"Osteoporos Int"},{"key":"335_CR113","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.amjmed.2007.12.012","volume":"121","author":"KM Berg","year":"2008","unstructured":"Berg KM, Kunins HV, Jackson JL et al (2008) Association between alcohol consumption and both osteoporotic fracture and bone density. Am J Med 121:406\u2013418","journal-title":"Am J Med"},{"key":"335_CR114","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"335_CR115","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"335_CR116","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell IR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"335_CR117","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"335_CR118","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"K Saag","year":"1998","unstructured":"Saag K, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. New Engl J Med 339:292\u2013299","journal-title":"New Engl J Med"},{"key":"335_CR119","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"S Wallach","year":"2000","unstructured":"Wallach S, Cohen S, Reid DM et al (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277\u2013285","journal-title":"Calcif Tissue Int"},{"key":"335_CR120","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer JP, Saag K et al (2009) Zoledronic acid and risedronate in the prevention and treatment of GIOP (HORIZON): a multicentre, double-blind, double-dummy, randomized controlled trail. Lancet 373:1253\u20131263","journal-title":"Lancet"},{"issue":"7","key":"335_CR121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11070","volume":"11","author":"JA Kanis","year":"2007","unstructured":"Kanis JA, Stevenson M, Mc Closkey EV et al (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assessment 11(7):1\u2013231","journal-title":"Health Technol Assessment"},{"key":"335_CR122","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2017-eular.1571","volume":"76","author":"A Makhzoum","year":"2017","unstructured":"Makhzoum A, Petriw L, Sattin M et al (2017) OP0049 Systematic review of randomized controlled trials evaluating bisphosphonates for the prevention and treatment of glucocorticoid-induced osteoporosis. Ann Rheum Dis 76:71\u201372","journal-title":"Ann Rheum Dis"},{"key":"335_CR123","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/ard.2010.143453","volume":"70","author":"CC Mok","year":"2011","unstructured":"Mok CC, Ying KY, To CH et al (2011) Raloxifene for prevention of glucocorticoid-induced bone loss: a 12\u00a0month randomized double-blinded placebo-controlled trial. Ann Rheum Dis 70:778\u2013784","journal-title":"Ann Rheum Dis"},{"key":"335_CR124","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/ard.2009.112920","volume":"69","author":"RK Dore","year":"2010","unstructured":"Dore RK, Cohen SB, Lane NE et al (2010) Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 69:872\u2013875","journal-title":"Ann Rheum Dis"},{"key":"335_CR125","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/art.21194","volume":"52","author":"JR Curtis","year":"2005","unstructured":"Curtis JR, Westfall AO, Allison JJ et al (2005) Longitudinal patterns in the prevention of glucocorticoid-treated patients. Arthritis Rheum 52:2485\u20132494","journal-title":"Arthritis Rheum"},{"key":"335_CR126","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00198-007-0345-9","volume":"18","author":"M Duyvendak","year":"2007","unstructured":"Duyvendak M, Naunton M, Atthobari J et al (2007) Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in the Netherlands 2001\u20132005. Ost Int 18:1429\u20131433","journal-title":"Ost Int"},{"key":"335_CR127","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-013-2562-8","volume":"25","author":"C Klop","year":"2014","unstructured":"Klop C, de Vries F, Vinks T et al (2014) Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback. Osteoporosis Int 25:385\u2013392","journal-title":"Osteoporosis Int"},{"key":"335_CR128","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"Saag KG, Zanchetta JR, Devogelaer JP et al (2009) Effects of teriparatide versus alendronate for testing glucocorticoid-induced osteoporosis: 36\u00a0months results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346\u20133355","journal-title":"Arthritis Rheum"},{"key":"335_CR129","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jbmr.1870","volume":"28","author":"CC Gluer","year":"2013","unstructured":"Gluer CC, Marin F, Ringe JD et al (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18\u00a0month results of the EuroGIOPs trial. J Bone Min Res 28:1355\u20131368","journal-title":"J Bone Min Res"},{"key":"335_CR130","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1021\/mp2000742","volume":"8","author":"JM Hoven Van de","year":"2011","unstructured":"Van de Hoven JM, van Tomme SR, Metselaar JM et al (2011) Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol Pharm 8:1002\u20131015","journal-title":"Mol Pharm"},{"key":"335_CR131","unstructured":"Barrera P MS, Smetsers AI, et al. (2008) Long-circulating liposomal prednisolone versus pulse intramuscular methylprednisolone in patients with active rheumatoid arthritis. ACR"},{"key":"335_CR132","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10928-016-9475-z","volume":"43","author":"DJ Conrado","year":"2016","unstructured":"Conrado DJ, Krishnaswami S, Shoji S et al (2016) Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose-response analysis. J Pharmacokinet Pharmacodyn 43:325\u2013341","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-017-0335-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-017-0335-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-017-0335-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T13:51:11Z","timestamp":1751205071000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-017-0335-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,8]]},"references-count":132,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1007\/s00223-017-0335-7","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,8]]}}}